Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Atea Pharmaceuticals Stock Down 1.0 %

AVIR stock opened at $3.03 on Friday. The company has a market cap of $255.92 million, a P/E ratio of -1.46 and a beta of 0.19. Atea Pharmaceuticals has a twelve month low of $2.75 and a twelve month high of $4.60. The business has a fifty day moving average of $3.19 and a 200-day moving average of $3.37.

Insider Transactions at Atea Pharmaceuticals

In other news, Director Franklin M. Berger sold 359,606 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now owns 451,897 shares in the company, valued at $1,287,906.45. The trade was a 44.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 17.80% of the stock is currently owned by corporate insiders.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.